Low dose atropine eye drops safe and effective for short-sightedness in children, clinical trial suggests
· Medical Xpressedited by Sadie Harley, reviewed by Robert Egan
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Associate Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Low-concentration atropine eye drops are a safe and effective treatment for short-sightedness (myopia) in UK children, although the effects are small, suggests a clinical trial published by The BMJ.
The researchers say the drops led to small but significant reductions in myopia progression compared with placebo and are "a worthwhile addition to currently available optical interventions for the treatment of myopia in children in the UK."
Rates of myopia in children are increasing worldwide and are linked to higher health care costs and long-term eye-related complications.
Atropine eye drops are used worldwide to treat myopia in children but are not currently available in the NHS, so their effectiveness and safety in children in the UK is uncertain.
To address this knowledge gap, researchers recruited 289 children with myopia ages 6–12 years (average age 9.3 years; 72% reported white ethnicity; 56% were girls) from five NHS hospital eye services and academic institutions between June 2019 and February 2022. All children wore standard spectacles to correct myopia.
A total of 192 children received daily 0.01% atropine eye drops and 97 received placebo for two years, in addition to standard spectacles. Myopia progression, eye growth, safety and tolerability were monitored every six months.
Final results were available for 230 children (151 in the atropine group and 79 in the placebo group).
After accounting for factors such as age, ethnicity and history of myopia in at least one parent, children who used atropine eye drops experienced a small decrease in myopia progression and eye growth compared with those using placebo drops.
Specifically, atropine treatment led to an average reduction of 0.38 D (diopter) in refractive error and 0.14 mm in central axial length—two key measures of myopia—compared with placebo.
Pupil diameter was the only other outcome with a notable difference (0.36 mm greater in the atropine group). No differences were seen in the frequency of adverse events or in tolerability measures, such as sore eyes, blurry vision, itchiness or difficulty reading and writing.
The researchers acknowledge several trial limitations, such as the generalizability of results outside of a clinical trial environment and the potential influence of the COVID-19 pandemic, which occurred during the trial period.
Nevertheless, they conclude, "The findings suggest that a low-concentration atropine eye drop product would be a worthwhile addition to currently available optical interventions for the treatment of myopia in children in the UK."
These results will help inform policymakers in the UK, they add.
Publication details
Low concentration atropine eye drops and progression of myopia in children: multicentre placebo controlled, double masked, randomised trial in the UK (CHAMP-UK), The BMJ (2026). DOI: 10.1136/bmj-2025-086698
Journal information: British Medical Journal (BMJ)
Key medical concepts
NearsightednessRefractive ErrorsPupil diameter
Clinical categories
OphthalmologyChildren's healthPediatrics Provided by British Medical Journal Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Low dose atropine eye drops safe and effective for short-sightedness in children, clinical trial suggests (2026, June 11) retrieved 11 June 2026 from https://medicalxpress.com/news/2026-06-dose-atropine-eye-safe-effective.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.